id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-6701-0008,FDA,FDA-2017-E-6701,Withdrawal of Application for Patent Term Extension,Other,Letter(s),2024-03-25T04:00:00Z,2024,3,2024-03-25T04:00:00Z,,2024-03-25T23:01:04Z,,0,0,090000648646a1b1
FDA-2017-E-6701-0007,FDA,FDA-2017-E-6701,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-09-17T04:00:00Z,2019,9,2019-09-17T04:00:00Z,,2019-09-17T13:44:50Z,,0,0,0900006483f86cca
FDA-2017-E-6701-0006,FDA,FDA-2017-E-6701,Determinations of Regulatory Review Periods for Purposes of Patent Extensions: RYDAPT,Notice,Determinations,2018-12-31T05:00:00Z,2018,12,2018-12-31T05:00:00Z,2019-06-27T03:59:59Z,2024-03-07T21:19:56Z,2018-28216,0,0,09000064839d2147
FDA-2017-E-6701-0005,FDA,FDA-2017-E-6701,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-12-21T05:00:00Z,2018,12,2018-12-21T05:00:00Z,,2018-12-21T17:40:37Z,,0,0,09000064839c04b3
FDA-2017-E-6701-0004,FDA,FDA-2017-E-6701,Letter from  the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2018-10-02T04:00:00Z,2018,10,2018-10-02T04:00:00Z,,2018-10-02T12:35:05Z,,0,0,090000648378ab01
FDA-2017-E-6701-0003,FDA,FDA-2017-E-6701,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2018-01-10T05:00:00Z,2018,1,2018-01-10T05:00:00Z,,2018-01-10T13:26:17Z,,0,0,0900006482dd38f1
FDA-2017-E-6701-0002,FDA,FDA-2017-E-6701,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2017-12-01T05:00:00Z,2017,12,2017-12-01T05:00:00Z,,2017-12-01T15:09:03Z,,0,0,0900006482cca2a1
FDA-2017-E-6701-0001,FDA,FDA-2017-E-6701,Patent Extension Application from Novartis Pharmaceuticals Corp,Other,Application,2017-12-01T05:00:00Z,2017,12,2017-12-01T05:00:00Z,,2017-12-01T15:03:03Z,,0,0,0900006482cca1f3